Literature DB >> 25551900

The appropriateness of a proton pump inhibitor prescription.

N Moran1, E Jones, A O'Toole, F Murray.   

Abstract

Proton pump inhibitors (PPIs) are one of the most commonly prescribed groups of drug in Ireland, at great expense to the Irish healthcare executive. This study aims to evaluate the appropriateness of PPI prescriptions on admission and discharge in a tertiary referral hospital. All non-elective admissions in the Emergency Department in one week were included in the study. 102 patients in total were included, with 36 (35.4%) treated with a PPI on admission. Of these, only 3 (8.3%) had a clear indication noted as per current NICE guidelines. 18 new in-hospital PPI prescriptions were documented. 11 (61%) of which were present on discharge prescriptions. Continuing PPI prescription on discharge into the community may be inappropriate, costly and potentially harmful. Brief interventions aimed at reducing inappropriate PPI prescriptions have been shown to be effective at reducing the cost and potential harm of unnecessary treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25551900

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  3 in total

1.  A cluster randomized trial to measure the impact on nonsteroidal anti-inflammatory drug and proton pump inhibitor prescribing in Italy of distributing cost-free paracetamol to osteoarthritic patients.

Authors:  Massimo Vicentini; Pamela Mancuso; Paolo Giorgi Rossi; Sara Di Pede; Morena Pellati; Alberto Gandolfi; Daniela Zoboli; Daniela Riccò; Corrado Busani; Alessandra Ferretti
Journal:  BMC Fam Pract       Date:  2019-12-06       Impact factor: 2.497

2.  Inappropriate Prescription of Proton Pump Inhibitors in a Community Setting.

Authors:  Patrick Viet-Quoc Nguyen; Raja Tamaz
Journal:  Can J Hosp Pharm       Date:  2018-08-28

3.  Identification of medication discrepancies during hospital admission in Jordan: Prevalence and risk factors.

Authors:  Lana Salameh; Rana Abu Farha; Iman Basheti
Journal:  Saudi Pharm J       Date:  2017-10-03       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.